Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Main Authors: | Amanda L. Piquet, John R. Corboy, Timothy L. Vollmer |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-05-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/17562864211019567 |
Similar Items
-
Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
by: Hela-Felicitas Petereit, et al.
Published: (2021-06-01) -
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
by: Anat Achiron, et al.
Published: (2021-05-01) -
Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
by: Anat Achiron, et al.
Published: (2021-04-01) -
Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
by: Rocco Capuano, et al.
Published: (2021-08-01) -
Integration of Immune Cell Populations, mRNA-Seq, and CpG Methylation to Better Predict Humoral Immunity to Influenza Vaccination: Dependence of mRNA-Seq/CpG Methylation on Immune Cell Populations
by: Gregory A. Poland, et al.
Published: (2017-04-01)